A5034473496- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Polyomavirus and related diseases
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Antifungal resistance and susceptibility
- Lung Cancer Treatments and Mutations
- Fungal Infections and Studies
- CNS Lymphoma Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Cancer Treatment and Pharmacology
- Mesenchymal stem cell research
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
Centre Hospitalier Universitaire de Bordeaux
2014-2023
Hôpital Cardiologique du Haut-Lévêque
2012-2021
Université de Bordeaux
2010-2020
Inserm
1996-2020
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2020
Centre Hospitalier Universitaire de Lille
2004-2019
Bordeaux Population Health
2015-2019
Polyclinique de Bordeaux-Tondu
2019
Université de Lille
2019
Lille Inflammation Research International Center
2019
Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may benefit in patients lymphoma.
To evaluate the efficacy and safety of voriconazole in acute invasive aspergillosis (IA), an open, noncomparative multicenter study was conducted. Immunocompromised patients with IA were treated intravenously administered 6 mg/kg twice a day (b.i.d.) then 3 b.i.d. for 6-27 days, followed by 200 mg orally up to 24 weeks. Response assessed clinical radiographic change. A total 116 assessable. proven 48 (41%) probable 68 patients. Voriconazole given as primary therapy 60 (52%). Good responses...
Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's (NHLs) in adults. ATCLs show a worse prognosis than B-cell lymphomas.On behalf the Société Française de Greffe Moëlle et Thérapie Cellulaire, we conducted retrospective analysis including 77 ATCL patients who underwent allogeneic stem-cell transplantation (alloSCT).The different diagnosis included anaplastic large-cell lymphoma (ALCL; n = 27), peripheral not otherwise specified (PTCL-NOS; angioimmunoblastic (AITL; 11),...
The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). impact of maintenance rituximab after ASCT not known.In total, 477 patients with CD20(+) DLBCL who were in their first relapse or refractory to initial randomly assigned one two regimens. After three cycles chemotherapy, the responding received ASCT. Then, 242 either every 2 months 1 year observation.After ASCT, 122...
Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated (UD) is limited and with controversial results. The study aim was to evaluate PT-Cy GVHD post-HSCT MSD UD transplants. We analyzed 423 patients acute leukemia who received alone combination other immunosuppressive (IS) drugs prophylaxis. Seventy-eight (group 1); 204 one IS drug—cyclosporine-A...
To compare hematologic recovery in patients receiving allogeneic blood cell transplantation (BCT) with those bone marrow (BMT).One hundred eleven leukemia the early stages and HLA-matched sibling donors were randomized this study. One one underwent transplantation. Standard procedures for collection used. Patients did not receive prophylactic granulocyte colony-stimulating factor after undergoing In addition to clinical end points being established, a prospective comparative economic...
The efficacy of first-line intensive chemotherapy plus transplantation autologous hematopoietic stem cells in adults with disseminated aggressive lymphoma is unknown.
To investigate the influence of donor type (human leukocyte antigen [HLA] -identical sibling versus HLA-A-, HLA-B-, HLA-Cw-, HLA-DRB1-, and HLA-DQB1-identical unrelated donors, or so-called 10/10) on outcome patients who underwent allogeneic stem-cell transplantation (alloSCT), adjusting for other prognostic factors, in with standard-risk hematologic malignancy.Between March 2000 January 2003, we prospectively investigated 236 consecutive malignancy from 12 French centers. Fifty-five alloSCT...
PURPOSE To compare the results achieved with myeloablative therapy followed by either allogeneic bone marrow transplantation (alloBMT) or autologous (ABMT) for patients Hodgkin's disease (HD). PATIENTS AND METHODS Of more than 1,200 HD reported to European Bone Marrow Transplantation (EBMT) registry, 49 underwent alloBMT. these, 45 sufficient data were matched who ABMT. The matching criteria sex, age at time of transplantation, stage diagnosis, involvement diagnosis and year status from...
We retrospectively investigated the feasibility and toxicity of autologous stem cell transplantation (ASCT) in 21 cases systemic amyloidosis (AL). The conditioning regimens consisted high-dose melphalan (HDM) alone (n = 18) or combination with 12 Gy total body irradiation 3). Toxic death rate was high: 9/21 patients (43%) died within first month following ASCT, 10/12 surviving achieved a response. With median follow-up 14 months, OS EFS rates at 4 years were 57.1% (+/-10.8) 29.9% (+/-14.5)...
Diffuse large B-cell lymphomas (DLBCL) are common that have been classified into three subgroups on the basis of their patterns gene expression. The aim this study was to characterize clinical, biological, immunophenotypic and cytogenetic features DLBCL with concurrent t(14;18) 8q24/c-MYC rearrangement.Sixteen cases dual translocation were identified between 1998 January 2006. clinical these examined morphological, immunohistochemical, flow cytometric analyses performed.All patients had...
To identify predictive factors of survival, relapse, and transplantation-related mortality (TRM) among patients with therapy-related myelodysplastic syndrome (t-MDS) or acute leukemia (t-AML) who underwent allogeneic bone marrow transplantation (BMT).From 1980 to 1998, 70 BMT for t-MDS (n = 31) t-AML 39) after prior cytotoxic exposure. Thirty-three had received induction-type chemotherapy before BMT. At the time transplantation, there were 24 in complete remission (CR) 46 active disease.With...
Purpose To analyze the outcome, including nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall (OS), of patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) relapsed after an autologous stem-cell transplantation (ASCT) treated allogeneic (allo-SCT). Patients Methods The European Group for Blood Marrow Transplantation database was scanned a first allo-SCT in DLBCL previous ASCT between 1997 2006. Other inclusion criteria were age at ≥ 18...